DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wjp3rj/breast_cancer) has announced the addition of the "Breast Cancer: New Targeted Therapies Transform Treatment - KOL Insight" report to their offering.
The introduction of targeted therapies revolutionised the breast cancer market, widening clinical options and bringing improved survival rates and lower side effects for patients. Now the sector is set for further positive change and expansion as next generation products for HER2-positive disease come to market, and CDK4/6 and P13K inhibitors hold the prospect of new treatments for hormone receptor-positive and HER2-negative breast cancer patients - an area of huge unmet clinical need. Which are the companies and products that will change the commercial and clinical landscape over the next 5 years?
This report will allow you to:
- Understand and evaluate the important drivers in targeted breast cancer treatments
- Fully evaluate how the competitive landscape may change
- Understand clinical opinions of current and futures products and how they will change treatment algorithms
- Survey and appraise the late-stage product pipeline
KOL Insight Benefits
- Understand and assess future breast cancer market developments
- Analyse current and future treatment algorithms
- Understand the strengths and weaknesses of currently available targeted therapies for breast cancer
- Assess how prescribing trends will change with launch of new products
- Identify promising late-stage pipeline products
- Track KOL opinion continuously over the next 12 months
Informing users in:
- Business development
- New product planning
- Strategic brand planning
- Market research
- Competitive Intelligence
- Forecasting and market analytics
- Medical affairs
- Clinical trials
- Relationship management
- Market Access
KOLs from North America:
Dr. Carlos L. Arteaga, MD is Associate Director for Clinical Research, Director, Breast Cancer Research Program, and Director, Center for Cancer Targeted Therapies at the Vanderbilt-Ingram Cancer Center (VICC), Vanderbilt University, Nashville, TN.
Dr. Kimberly L. Blackwell, MD is Professor of Medicine and Assistant Professor of Radiation Oncology at Duke University Medical Center, Durham, NC.
Dr. Adam M. Brufsky, MD, PhD is Professor of Medicine at the University of Pittsburgh School of Medicine, Pittsburgh, PA.
Dr. Ana Maria Gonzalez-Angulo, MD, MSc, FACP is Associate Professor, Department of Breast Medical Oncology and Chief, Section of Clinical Research and Drug Development, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Dr. Reshma Mahtani, DO is Assistant Professor of Clinical Medicine, Division of Hematology/Oncology, Miller School of Medicine, University of Miami, Miami, FL.
Dr. Charles Vogel, MD is Professor of Clinical Medicine, Division of Hematology/Oncology, Miller School of Medicine, University of Miami, Miami, FL.
KOLs from Europe:
Dr. Thomas Bachelot, MD is Head of the Breast Cancer Unit and the Clinical Trial Unit at the Centre Leon Berard, Lyon, France.
Dr. Rob Coleman, MBBS, MD, FRCP is Professor Department of Oncology, Weston Park Hospital, Sheffield, England, UK.
Dr. Alessandra Gennari, MD, PhD is Medical Director, Medical Oncology Unit, Galliera Hospital, Genoa, Italy.
Dr. Adrian L. Harris, MD, DPhil is Professor of Medical Oncology at the University of Oxford and Director of the Cancer Research UK Medical Oncology Unit.
Professor Gunter von Minckwitz is Managing Director of the German Breast Group (GBG) Research Institute.
Dr. Rafael Trujillo is Medical Oncologist, Xanit International Hospital, Malaga, Spain.
For more information visit http://www.researchandmarkets.com/research/wjp3rj/breast_cancer